This study circumvented the shortcomings of previous studies to some extent, analyzed the differences in SUVmax, TL-PSMAp, and PSMA-TVp of PET/CT in patients with different numbers of metastatic lesions (none, oligometastatic, and extensive metastasis), and selected the most clinically significant metabolic parameters of PET/CT that truly reflected tumor behavior, distribution, and invasiveness. The gene discussed is FOLH1; the disease is neoplasm.